AZ-话题@MedSci

#AZ#

260篇内容 | 3619人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1714938, encodeId=874c1e14938d4, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=FDA批准oteseconazole（奥特康唑）用于复发性外阴阴道假丝酵母菌病治疗, objectType=article, longId=725781, objectId=a0c3e2578110, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0c3e2578110, replyNumber=0, likeNumber=85, createdTime=2022-11-16, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0c3e2578110, moduleTitle=FDA批准oteseconazole（奥特康唑）用于复发性外阴阴道假丝酵母菌病治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0c3e2578110)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714937, encodeId=6cef1e1493717, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, objectType=article, longId=723981, objectId=f235e2398163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f235e2398163, replyNumber=0, likeNumber=96, createdTime=2022-08-31, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f235e2398163, moduleTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f235e2398163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714942, encodeId=44ef1e149422b, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=NEJM：Fazirsiran 治疗α1-抗胰蛋白酶缺乏症相关的肝病, objectType=article, longId=730625, objectId=6524e3062522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6524e3062522, replyNumber=0, likeNumber=83, createdTime=2023-03-06, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6524e3062522, moduleTitle=NEJM：Fazirsiran 治疗α1-抗胰蛋白酶缺乏症相关的肝病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6524e3062522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714946, encodeId=70791e149468c, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz J Otorhinolaryngol：头颈部皮肤鳞状细胞癌和基底细胞癌的细胞动力学标志物, objectType=article, longId=738416, objectId=a32de3841614, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a32de3841614, replyNumber=0, likeNumber=92, createdTime=2022-11-08, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a32de3841614, moduleTitle=Braz J Otorhinolaryngol：头颈部皮肤鳞状细胞癌和基底细胞癌的细胞动力学标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a32de3841614)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714944, encodeId=3cf41e14944ee, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Mazdutide (IBI362) 在中国超重或肥胖2型糖尿病II期临床研究达到主要终点, objectType=article, longId=732770, objectId=2432e3277073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2432e3277073, replyNumber=0, likeNumber=90, createdTime=2023-02-06, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2432e3277073, moduleTitle=Mazdutide (IBI362) 在中国超重或肥胖2型糖尿病II期临床研究达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2432e3277073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714943, encodeId=7acb1e149430c, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=《新英格兰医学杂志》发表Fazirsiran治疗α-1抗胰蛋白酶缺乏症患者的二期研究结果, objectType=article, longId=730850, objectId=e34ae3085081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e34ae3085081, replyNumber=0, likeNumber=115, createdTime=2023-01-01, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e34ae3085081, moduleTitle=《新英格兰医学杂志》发表Fazirsiran治疗α-1抗胰蛋白酶缺乏症患者的二期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e34ae3085081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714940, encodeId=09ca1e1494025, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=NEJM：单克隆抗体AZD7442可有效降低新冠肺炎易感人群感染风险, objectType=article, longId=729467, objectId=e598e2946758, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e598e2946758, replyNumber=0, likeNumber=116, createdTime=2023-02-22, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e598e2946758, moduleTitle=NEJM：单克隆抗体AZD7442可有效降低新冠肺炎易感人群感染风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e598e2946758)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714932, encodeId=25a11e1493293, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=JCEM：靶向11- β羟化酶[131I]IMAZA -一种治疗晚期肾上腺皮质癌的新方法, objectType=article, longId=292074, objectId=09292920e457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09292920e457, replyNumber=0, likeNumber=120, createdTime=2022-02-18, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09292920e457, moduleTitle=JCEM：靶向11- β羟化酶[131I]IMAZA -一种治疗晚期肾上腺皮质癌的新方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09292920e457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714945, encodeId=1cef1e1494570, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌, objectType=article, longId=736915, objectId=4bffe369156f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bffe369156f, replyNumber=0, likeNumber=95, createdTime=2022-10-26, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bffe369156f, moduleTitle=Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bffe369156f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714941, encodeId=6b0b1e149417e, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=乳糜泻候选药物Larazotide 3期试验失败, objectType=article, longId=730267, objectId=02f7e30267b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02f7e30267b6, replyNumber=0, likeNumber=94, createdTime=2023-05-07, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02f7e30267b6, moduleTitle=乳糜泻候选药物Larazotide 3期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02f7e30267b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714930, encodeId=e9461e14930b2, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), objectType=article, longId=291939, objectId=aea92919392a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aea92919392a, replyNumber=0, likeNumber=94, createdTime=2022-05-17, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aea92919392a, moduleTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aea92919392a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714933, encodeId=a87a1e14933ab, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz J Otorhinolaryngol：使用RSI和RFS评分来区分慢性喉炎的不同病因, objectType=article, longId=293236, objectId=20562932366b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20562932366b, replyNumber=0, likeNumber=139, createdTime=2022-01-28, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20562932366b, moduleTitle=Braz J Otorhinolaryngol：使用RSI和RFS评分来区分慢性喉炎的不同病因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20562932366b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714931, encodeId=01361e14931b3, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=NEJM：AZD1222疫苗对Covid-19安全性和有效性如何？, objectType=article, longId=292087, objectId=b8dc29208e9e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8dc29208e9e, replyNumber=0, likeNumber=116, createdTime=2022-04-27, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8dc29208e9e, moduleTitle=NEJM：AZD1222疫苗对Covid-19安全性和有效性如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8dc29208e9e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714921, encodeId=02c41e14921dd, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=武田和Frazier Healthcare Partners宣布合作成立HilleVax, Inc.以开发临床阶段诺如病毒候选疫苗, objectType=article, longId=215179, objectId=45d52151e9f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45d52151e9f8, replyNumber=0, likeNumber=81, createdTime=2021-09-24, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45d52151e9f8, moduleTitle=武田和Frazier Healthcare Partners宣布合作成立HilleVax, Inc.以开发临床阶段诺如病毒候选疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45d52151e9f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714934, encodeId=bad81e14934e7, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, objectType=article, longId=293988, objectId=5aae293988cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aae293988cd, replyNumber=0, likeNumber=105, createdTime=2022-11-13, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aae293988cd, moduleTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5aae293988cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714939, encodeId=9e061e149392b, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=AP&T: 新型钾竞争性酸阻滞剂克维拉赞(keverprazan)治疗糜烂性食管炎的疗效和安全性分析, objectType=article, longId=728067, objectId=b454e280675c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b454e280675c, replyNumber=0, likeNumber=126, createdTime=2022-08-08, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b454e280675c, moduleTitle=AP&T: 新型钾竞争性酸阻滞剂克维拉赞(keverprazan)治疗糜烂性食管炎的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b454e280675c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714920, encodeId=e2141e149201b, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物, objectType=article, longId=214645, objectId=1284214645f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1284214645f5, replyNumber=0, likeNumber=103, createdTime=2021-09-13, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1284214645f5, moduleTitle=Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1284214645f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714926, encodeId=55b31e1492661, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), objectType=article, longId=217348, objectId=9f0d21e348f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f0d21e348f1, replyNumber=0, likeNumber=88, createdTime=2022-01-29, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f0d21e348f1, moduleTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f0d21e348f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714936, encodeId=9e2f1e1493636, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=FDA要求阿斯利康（AstraZeneca）提供更多关于的Fasenra治疗慢性鼻窦炎伴鼻息肉的数据, objectType=article, longId=300798, objectId=f582300e985d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f582300e985d, replyNumber=0, likeNumber=107, createdTime=2022-06-07, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f582300e985d, moduleTitle=FDA要求阿斯利康（AstraZeneca）提供更多关于的Fasenra治疗慢性鼻窦炎伴鼻息肉的数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f582300e985d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714915, encodeId=448c1e1491596, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=阿斯利康称其抗体疗法AZD7442预防有症状新冠肺炎效果未达主要目标, objectType=article, longId=212790, objectId=df31212e901a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df31212e901a, replyNumber=0, likeNumber=93, createdTime=2021-08-31, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df31212e901a, moduleTitle=阿斯利康称其抗体疗法AZD7442预防有症状新冠肺炎效果未达主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df31212e901a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AZ

2020-05-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

FDA批准oteseconazole（奥特康唑）用于复发性外阴阴道假丝酵母菌病治疗

2022-11-16

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验

2022-08-31

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

NEJM：Fazirsiran 治疗α1-抗胰蛋白酶缺乏症相关的肝病

2023-03-06

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz J Otorhinolaryngol：头颈部皮肤鳞状细胞癌和基底细胞癌的细胞动力学标志物

2022-11-08

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Mazdutide (IBI362) 在中国超重或肥胖2型糖尿病II期临床研究达到主要终点

2023-02-06

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

《新英格兰医学杂志》发表Fazirsiran治疗α-1抗胰蛋白酶缺乏症患者的二期研究结果

2023-01-01

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

NEJM：单克隆抗体AZD7442可有效降低新冠肺炎易感人群感染风险

2023-02-22

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

JCEM：靶向11- β羟化酶[131I]IMAZA -一种治疗晚期肾上腺皮质癌的新方法

2022-02-18

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌

2022-10-26

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

乳糜泻候选药物Larazotide 3期试验失败

2023-05-07

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C)

2022-05-17

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz J Otorhinolaryngol：使用RSI和RFS评分来区分慢性喉炎的不同病因

2022-01-28

12498e5fm22(暂无昵称) (审核中...)